UNSPSC 51132240: Aspirin/magnesium oxide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.

UNSPSC 51132240 Aspirin/magnesium oxide is a Commodity code under which state and local governments procure pharmaceutical products and over-the-counter medications to support community health programs, emergency response initiatives, and population health management. Recent activity shows state and local buyers sourcing generic multi-source pharmaceuticals, naloxone and drug deactivation systems, and prescription fulfillment capabilities through a mix of direct county health procurement and cooperative purchasing vehicles. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance). The code attracts manufacturers and authorized pharmaceutical wholesalers who must comply with FDA manufacturing practices, Drug Supply Chain Security Act requirements, and state-specific procurement frameworks.

Recent activity concentrates in Florida, Texas, and the Upper Midwest. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for a direct-to-manufacturer prescriptions program outside traditional pharmacy benefit manager channels, reflecting state interest in alternative distribution and pricing models. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 on January 20, 2026, with a March 26, 2026 response deadline, to establish multi-award contracts for generic pharmaceuticals and OTC products distributed through authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) across participating state and local facilities including Oregon. Vendors must demonstrate cGMP compliance, maintain relationships with at least two of the three authorized wholesalers, accept a 3 percent administrative fee, and provide pricing in flat-price or net-price formats effective July 1, 2026.